| MLTX |
MoonLake Immunotherapeutics |
Class A ordinary share, par value $0.0001 per share |
28% |
$141,616,706 |
|
19,751,284 |
|
BVF PARTNERS L P/IL |
06 Nov 2025 |
| XOMA |
XOMA Royalty Corp |
Common Stock, $0.0075 par value |
22% |
$63,747,357 |
-$9,664,913 |
2,590,303 |
-13% |
BVF GP HOLDINGS LLC |
16 May 2025 |
| GHRS |
GH Research PLC |
Ordinary Shares, nominal value $0.025 per share |
14% |
$84,128,095 |
|
8,827,712 |
|
BVF PARTNERS L P/IL |
31 Mar 2025 |
| XNCR |
Xencor Inc |
Common Stock, par value $0.01 per share |
10% |
$109,217,253 |
+$38,495,142 |
7,133,720 |
+54% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| KURA |
Kura Oncology, Inc. |
Common Stock, par value $0.0001 per share |
10% |
$76,791,609 |
+$24,465,506 |
8,677,018 |
+47% |
BVF PARTNERS L P/IL |
30 Sep 2025 |
| CGEM |
Cullinan Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
10% |
$64,748,182 |
|
5,918,481 |
|
BVF PARTNERS L P/IL |
31 Dec 2025 |
| FDMT |
4D Molecular Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
10% |
$45,959,629 |
+$9,546,222 |
5,847,281 |
+26% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| AVTX |
Avalo Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
10% |
$32,277,156 |
+$7,561,497 |
1,904,257 |
+31% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| CBIO |
CRESCENT BIOPHARMA, INC. |
Ordinary Shares, $0.001 par value per share |
10% |
$18,736,150 |
|
1,387,863 |
|
BVF PARTNERS L P/IL |
30 Jun 2025 |
| TENX |
TENAX THERAPEUTICS, INC. |
Common Stock, $0.0001 par value per share |
10% |
$11,561,410 |
|
768,200 |
|
BVF PARTNERS L P/IL |
31 Dec 2025 |
| TCRX |
TScan Therapeutics, Inc. |
Voting Common Stock, $0.0001 par value per share |
10% |
$8,421,666 |
|
5,263,541 |
|
BVF PARTNERS L P/IL |
31 Mar 2025 |
| IMUX |
IMMUNIC, INC. |
Common Stock, $0.0001 par value |
10% |
$8,314,667 |
+$2,345,708 |
13,630,601 |
+39% |
BVF PARTNERS L P/IL |
12 Feb 2026 |
| UNCY |
Unicycive Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
10% |
$7,439,864 |
|
1,417,117 |
|
BVF PARTNERS L P/IL |
30 Jun 2025 |
| VTGN |
Vistagen Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
10% |
$7,217,318 |
|
3,084,324 |
|
BVF PARTNERS L P/IL |
31 Dec 2024 |
| SABS |
SAB Biotherapeutics, Inc. |
Common Stock, $0.0001 par value per share |
9.1% |
$18,761,910 |
-$1,598,505 |
4,761,906 |
-7.9% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| IVVD |
Invivyd, Inc. |
Common Stock, $0.0001 par value per share |
9% |
$64,323,000 |
+$24,003,000 |
25,525,000 |
+60% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| KYMR |
Kymera Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
8.5% |
$436,311,906 |
|
6,867,809 |
|
BVF PARTNERS L P/IL |
11 Dec 2025 |
| IKNA |
Ikena Oncology, Inc. |
Common Stock, par value $0.001 per share |
8.3% |
$4,246,958 |
|
4,006,564 |
|
BVF PARTNERS L P/IL |
31 Dec 2024 |
| STRO |
SUTRO BIOPHARMA, INC. |
Common Stock, $0.001 par value |
7.6% |
$13,306,506 |
|
1,251,788 |
|
BVF PARTNERS L P/IL |
10 Feb 2026 |
| NKTR |
NEKTAR THERAPEUTICS |
Common Stock, $0.0001 par value |
7.4% |
$32,978,662 |
|
1,276,595 |
|
BVF PARTNERS L P/IL |
01 Jul 2025 |
| IMA |
ImageneBio, Inc. |
Common Stock, par value $0.001 per share |
7.2% |
$6,538,736 |
|
802,102 |
|
BVF PARTNERS L P/IL |
30 Sep 2025 |
| PVLA |
PALVELLA THERAPEUTICS, INC. |
Common Stock, $0.001 par value per share |
7.1% |
$88,331,614 |
-$30,366,571 |
879,009 |
-26% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| ELEV |
Elevation Oncology, Inc. |
Common Stock, par value $0.0001 per share |
7% |
$1,642,800 |
|
4,440,000 |
|
BVF PARTNERS L P/IL |
31 Mar 2025 |
| GLUE |
Monte Rosa Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
5.9% |
$92,022,905 |
-$43,763,662 |
3,835,886 |
-32% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| ZYME |
Zymeworks Inc. |
Common Stock, $0.00001 par value per share |
5.2% |
$67,271,988 |
|
3,938,641 |
|
BVF PARTNERS L P/IL |
30 Sep 2025 |
| CMPX |
Compass Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
5.1% |
$30,625,000 |
|
8,750,000 |
|
BVF PARTNERS L P/IL |
22 Oct 2025 |
| IVA |
Inventiva S.A. |
Ordinary Shares, nominal value (euro)0.01 per share |
5% |
$39,714,931 |
+$4,251,111 |
9,569,863 |
+12% |
BVF PARTNERS L P/IL |
17 Nov 2025 |
| GPCR |
Structure Therapeutics Inc. |
Ordinary Shares, par value $0.0001 per share |
4.9% |
$723,914,898 |
+$57,243,848 |
10,437,066 |
+8.6% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| CDTX |
Cidara Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
4.4% |
$113,871,586 |
-$21,545,460 |
1,189,165 |
-16% |
BVF PARTNERS L P/IL |
15 Oct 2025 |
| PTGX |
Protagonist Therapeutics, Inc |
Common Stock, $0.00001 par value per share |
4.1% |
$170,121,650 |
-$43,187,804 |
2,560,916 |
-20% |
BVF PARTNERS L P/IL |
30 Sep 2025 |
| TYRA |
Tyra Biosciences, Inc. |
Common Stock, $0.0001 par value per share |
4% |
$64,574,633 |
-$55,131,655 |
2,127,665 |
-46% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| XFOR |
X4 Pharmaceuticals, Inc |
Common Stock, par value $0.001 per share |
3.9% |
$13,272,653 |
+$4,544,819 |
3,411,993 |
+52% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| VSTM |
Verastem, Inc. |
Common Stock, $0.0001 par value per share |
3.9% |
$11,850,000 |
-$15,266,739 |
2,500,000 |
-56% |
BVF PARTNERS L P/IL |
11 Aug 2025 |
| SEPN |
Septerna, Inc. |
Common Stock, $0.001 par value per share |
3.8% |
$42,813,056 |
-$66,562,509 |
1,720,782 |
-61% |
BVF PARTNERS L P/IL |
31 Dec 2025 |
| ETNB |
89bio, Inc. |
Common Stock, par value $0.001 per share |
3.6% |
$29,903,806 |
|
4,333,885 |
|
BVF PARTNERS L P/IL |
31 Dec 2024 |
| CTMX |
CytomX Therapeutics, Inc. |
Common Stock, $0.00001 par value per share |
3.5% |
$17,250,001 |
-$17,250,001 |
5,769,231 |
-50% |
BVF PARTNERS L P/IL |
03 Jul 2025 |
| MIRM |
Mirum Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
3% |
$109,619,710 |
|
1,495,290 |
|
BVF PARTNERS L P/IL |
30 Sep 2025 |
| ENGN |
enGene Holdings Inc. |
Common Shares, no par value per share |
1.8% |
$3,781,608 |
-$8,424,148 |
945,402 |
-69% |
BVF PARTNERS L P/IL |
27 Jan 2025 |
| CELC |
Celcuity Inc. |
Common Stock, $0.001 par value per share |
1.6% |
$32,525,997 |
|
658,421 |
|
BVF PARTNERS L P/IL |
30 Sep 2025 |
| NLSP |
NewcelX Ltd. |
Common Shares, par value CHF 0.05 |
0.6% |
|
|
28,732 |
|
BVF PARTNERS L P/IL |
31 Oct 2025 |
| FBRX |
Forte Biosciences, Inc. |
Common Stock, $0.001 par value |
0.5% |
$980,250 |
-$8,674,080 |
65,350 |
-90% |
BVF PARTNERS L P/IL |
30 Sep 2025 |
| RPTX |
Repare Therapeutics Inc. |
Common Shares, no par value |
0% |
$0 |
-$26,867,360 |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
28 Jan 2026 |
| VIGL |
Vigil Neuroscience, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
-$38,112,725 |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
30 Jun 2025 |
| ITOS |
iTeos Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
0% |
$0 |
-$31,641,750 |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
30 Jun 2025 |
| THRD |
Third Harmonic Bio, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
BIOTECHNOLOGY VALUE FUND L P |
14 Apr 2025 |
| RAPT |
RAPT Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
0% |
$0 |
-$303,393,560 |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
30 Sep 2025 |
| EPIX |
ESSA Pharma Inc. |
Common Shares |
0% |
$0 |
-$2,800,434 |
0 |
-100% |
BIOTECHNOLOGY VALUE FUND L P |
09 Oct 2025 |
| OVID |
Ovid Therapeutics Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
BIOTECHNOLOGY VALUE FUND L P |
17 Jul 2025 |
| VERV |
Verve Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
BIOTECHNOLOGY VALUE FUND L P |
30 Jun 2025 |
| ALLK |
Allakos Inc. |
Common Stock, par value $0.001 |
0% |
$0 |
|
0 |
|
BIOTECHNOLOGY VALUE FUND L P |
15 May 2025 |